New Transcatheter Mitral Prosthesis: The First 100 Patients
March 26, 2019
Published in JACC is the largest experience to date. The prosthesis was highly effective in relieving mitral regurgiation and improving symptoms, with an acceptable safety profile.
Transcatheter mitral valve replacement (TMVR) is a rapidly evolving therapy. Follow-up of TMVR patients remains limited in duration and number treated. A new article published in JACC by Dr. Paul Sorajja et al., reports the initial results of the Abbott Tendyne Transcatheter Mitral Valve Replacement (TMVR) system. The device is designed for the treatment of mitral regurgitation (MR) without the need for open-heart surgery. A total of 100 patients were treated with this valve and followed up for a year.
The Tendyne valve may provide a life-saving treatment option for MR patients by replacing their native mitral valve without open-heart surgery to reduce their heart failure symptoms. The device is a tri-leaflet, bioprosthetic valve available in multiple sizes, and is stabilized by a pad and a tether mechanism that holds the pad in place where it’s been implanted inside the native valve. As the first and only repositionable and fully retrievable replacement valve, Tendyne can conform to a broad range of anatomies, which may allow for better outcomes and procedural ease-of-use.
In this study of TMVR, which is the largest experience to date, the prosthesis was highly effective in relieving MR and improving symptoms, with an acceptable safety profile. The study concludes that further study to optimize the impact on long-term survival is needed.